Senate approves measure to recognize federal drug rescheduling for prescription access
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
Senate Bill 31, which directs Colorado to treat FDA/DEA-approved rescheduling of certain prescription products containing a schedule I substance like other prescription drugs (removing a separate state rescheduling path), passed the Senate Feb. 23, 2026, after a technical clarifying amendment.
The Colorado Senate adopted Senate Bill 31 on Feb. 23, 2026, which aligns the state’s scheduling treatment for prescription products containing a Schedule I controlled substance with subsequent federal rescheduling actions.
Senator Rich described the bill as reducing duplicative state regulatory steps by allowing drugs rescheduled at the federal level (FDA and DEA approvals) to be dispensed in Colorado like other prescription medications. The health committee had adopted an amendment (L001) to clarify that only FDA- and DEA-approved schedule changes are covered; the floor adopted a clarifying amendment (L002) to ensure natural medicine is excluded from the bill’s scope.
Supporters said the change reduces regulatory delay and may lower administrative cost; no substantive opposition emerged on the floor. The Senate adopted the bill after voice votes on committee report and floor amendments.
Next steps: SB31 was ordered engrossed and placed on the calendar for third reading and final passage as recorded in the Committee of the Whole report and floor action on Feb. 23, 2026.